Abstract
The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
Keywords:
COVID-19; SARS-CoV-2; vaccine.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antigens, Viral / chemistry
-
Antigens, Viral / genetics
-
Betacoronavirus* / genetics
-
Betacoronavirus* / immunology
-
COVID-19
-
COVID-19 Vaccines
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / immunology*
-
Coronavirus Infections / prevention & control*
-
Host Microbial Interactions / immunology
-
Humans
-
Immunity, Cellular
-
Immunity, Humoral
-
Immunity, Innate
-
Models, Animal
-
Pandemics / prevention & control*
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / immunology*
-
Pneumonia, Viral / prevention & control*
-
Primates
-
SARS-CoV-2
-
Spike Glycoprotein, Coronavirus / chemistry
-
Spike Glycoprotein, Coronavirus / genetics
-
Spike Glycoprotein, Coronavirus / immunology
-
Viral Vaccines / administration & dosage
-
Viral Vaccines / immunology
-
Viral Vaccines / isolation & purification*
Substances
-
Antigens, Viral
-
COVID-19 Vaccines
-
Spike Glycoprotein, Coronavirus
-
Viral Vaccines
-
spike protein, SARS-CoV-2